Objective-We sought to discover proteins that associate with estrogen receptor beta (ER␤) and modulate estrogen signaling. Methods and Result-Using a yeast 2-hybrid screen, we identified heat shock protein 27 (HSP27) as an ER␤-associated protein. HSP27 is a recently identified biomarker of atherosclerosis that is secreted at reduced levels from atherosclerotic compared with normal arteries. In vitro protein-binding assays confirmed the specific interaction of HSP27 with ER␤ and not ER␣. HSP27 expression was absent in coronary arteries with complex atherosclerotic lesions. Interestingly, HSP27 expression was also absent in 60% of coronary arteries from young males and females (27Ϯ6.5 years) with normal histology or nonobstructive fatty streaks/atheromas. Moreover, the absence of HSP27 in these normal or minimally diseased arteries coincided with the loss of ER␤ expression. Only 35% of arteries showed coexpression of HSP27 and ER␤. Relative to controls, estradiol-mediated transcription was reduced 20% with overexpression of HSP27 and increased 44% when HSP27 protein levels were reduced with HSP27 siRNA. Conclusions-HSP27, an ER␤-associated protein, shows attenuated expression with coronary atherosclerosis and modulates estrogen signaling. here is a sex bias in the prevalence of cardiovascular morbidity and mortality that favors women until menopause; thereafter, this difference is lost. 1 Although a plausible explanation for this epidemiological distinction is the presumed vasculoprotective effect of ovarian hormones, randomized primary and secondary prevention trials involving hormone replacement therapy not only are nonconfirmatory but also document ill effects. [2] [3] [4] Estrogens act via at least 2 receptors that are expressed in the vessel wall (ER␣ and ER␤), although there is increasing evidence that receptorassociated proteins play a critical role in determining the biological responses to ligand-dependent and ligandindependent signaling. 1, [5] [6] [7] [8] [9] We hypothesized that coregulators of ERs may modulate estrogen signaling in vascular tissues. In this article, we report that heat shock protein 27 (HSP27), a recently reported potential biomarker of atherosclerosis, specifically interacts with estrogen receptor beta (ER␤)-the receptor isoform that shows transient mRNA overexpression early after vascular injury. 10 -12 Using a differential proteomic screening approach, HSP27 secretion levels from human carotid plaques were found to be markedly diminished compared with normal arteries. 10 Moreover, circulating blood levels of HSP27 were decreased in patients with carotid atherosclerosis relative to healthy subjects. We now demonstrate that expression of HSP27 diminishes as the stage of coronary atherosclerosis progresses and that HSP27 is capable of regulating estrogen mediated transcription in vitro.
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here is a sex bias in the prevalence of cardiovascular morbidity and mortality that favors women until menopause; thereafter, this difference is lost. 1 Although a plausible explanation for this epidemiological distinction is the presumed vasculoprotective effect of ovarian hormones, randomized primary and secondary prevention trials involving hormone replacement therapy not only are nonconfirmatory but also document ill effects. [2] [3] [4] Estrogens act via at least 2 receptors that are expressed in the vessel wall (ER␣ and ER␤), although there is increasing evidence that receptorassociated proteins play a critical role in determining the biological responses to ligand-dependent and ligandindependent signaling. 1, [5] [6] [7] [8] [9] We hypothesized that coregulators of ERs may modulate estrogen signaling in vascular tissues. In this article, we report that heat shock protein 27 (HSP27), a recently reported potential biomarker of atherosclerosis, specifically interacts with estrogen receptor beta (ER␤)-the receptor isoform that shows transient mRNA overexpression early after vascular injury. 10 -12 Using a differential proteomic screening approach, HSP27 secretion levels from human carotid plaques were found to be markedly diminished compared with normal arteries. 10 Moreover, circulating blood levels of HSP27 were decreased in patients with carotid atherosclerosis relative to healthy subjects. We now demonstrate that expression of HSP27 diminishes as the stage of coronary atherosclerosis progresses and that HSP27 is capable of regulating estrogen mediated transcription in vitro.
Materials and Methods
Briefly, our studies involve 4 major components: (1) the use of a yeast 2-hybrid screen to identify proteins that associate with the unique A/B domain of ER␤; (2) the in vitro confirmation of the association of HSP27 with ER␤ and not ER␣; (3) the demonstration of HSP27 expression in human coronary arteries; and (4) determination of the effect of modulating HSP27 levels on estrogen signaling. For a detailed account of the methodologies used in this article, please see http://atvb.ahajournals.org.
Results

HSP27 Interacts Specifically With the A/B Domain of ER␤
Using a yeast 2-hybrid screen, we identified previously unreported protein interactions with the ER␤. We selected the A/B domain of ER␤ as our "bait" because it shares only 30% sequence identity with ER␣. Dual-reporter gene activity (LEU2 and ␤-galactosidase) identified 77 positive screening results from a human lung fibroblast cell line cDNA library that contained 5.3ϫ10 6 clones. Restriction enzyme analysis identified duplicate clones, and the unique clones were sequenced. Because the A/B domain of ER␤ contains the transcriptional activation function AF1, we ensured that selection gene expression was dependent on the interaction with the candidate proteins and not simply caused by auto-activation. Discounting ferritin and ribosomal proteins, which are commonly reported false-positives (http:// www.fccc.edu/research/labs/golemis/), 3 unique clones remained: B8, D6, and HSP27 (BC073768; Figure 1A and 1B). All screens were repeated in triplicate to ensure the validity of the interactions. The HSP27 clone shared 98.7% sequence identity with the HSP27 protein sequence in the open reading frame ( Figure 1C ).
To confirm our yeast 2-hybrid findings, we used 2 separate in vitro assays. First, a fusion protein pull-down assay was performed using MBP column precipitation. Fusion proteins of ER␤-MBP and HSP27-intein were expressed in bacteria, and then cell lysates were isolated. The ER␤-MBP protein was immobilized in a column before either HSP27-intein or nonfused intein cell lysates were run through the column. The retained product was then isolated and analyzed by Western blot with an intein-specific probe. With the empty intein construct, minimal protein was retained in the column, indicating that intein alone interacted only weakly with the ER␤-MBP product (ie, background; Figure 1D ). However, the HSP27-intein fusion construct resulted in much darker band, consistent with a greater retention of protein and a strong HSP27 and ER␤ interaction. Second, coimmunoprecipitation of the 2 proteins was performed. HeLa cells were transfected with either an ER␤-DsRed fusion construct (alone) or both ER␤-DsRed and HSP27-EGFP fusion protein constructs. An anti-DsRed antibody was used to immunoprecipitate proteins that bound to ER␤, and isolated proteins were analyzed by Western blot analysis using an HSP27 specific antibody. In HeLa cells transfected with the ER␤ construct alone a weak band was observed-consistent with nonspecific binding ( Figure 1E ). In HeLa cells cotransfected with both the ER␤ and HSP27 fusion protein constructs, the 50-kDa HSP27-EGFP fusion protein was immunoprecipitated, thereby indicating a specific interaction between ER␤ and HSP27.
To ensure that HSP27 specifically interacted with ER␤ and not ER␣, coimmunoprecipitation of HeLa cell lysate from cells transfected with either an ER␣ or an ER␤ expression vector was performed with an anti-HSP27 antibody. The precipitate was then analyzed by Western blot with both ER␤-specific and ER␣-specific antibodies. The anti-HSP27 antibody clearly immunoprecipitated ER␤ but failed to demonstrate an appreciable signal above background levels for ER␣ ( Figure 1F ).
HSP27 Is Coexpressed With ER␤ in the Coronary Arteries of Young Individuals
The expression of ER␤ and HSP27 was examined in coronary arteries with advanced atherosclerosis, as well as the proximal LAD of 20 young human subjects who died of noncardiovascular causes (14 men and 6 women; age: 27Ϯ6.5 years). HSP27 expression was absent in those arteries with advanced atherosclerotic lesions (Figure 2A and 2B) . However, in coronary arteries with benign intimal hyperplasia or nonobstructive, pathological fatty streaks and/or atheromas (Stary type I and type III lesions, respectively), we noted variable expression of both HSP27 and ER␤ ( Figure 2C to 2F). The endothelium was present in all arteries, thereby discounting the possibility that false-negative immunolabeling results were the result of a denuded endothelium ( Figure  2G ). In these arteries, the following relationships were noted for the expression of HSP27 and ER␤: 7 of 20 (35%) were immunopositive for both, whereas 12 of 20 (60%) were negative for both ( Figure 2H ). Only one artery was immunopositive for HSP27 but lacked immunodetectable ER␤. No histological features were predictive of HSP27 or ER␤ 
HSP27 Estradiol Mediated Transcriptional Activity
Finally, we examined the role of HSP27 in modulating the estrogen transcriptional activity in HeLa cells stably transfected with an estrogen response element (ERE)-driven EGFP reporter. First, we examined the effect of elevated HSP27 levels on estrogen signaling by inducing overexpression of endogenous HSP27 by treating the cells with H 2 O 2 , a form of oxidative stress ( Figure 3A) . 13 Induction of HSP27 overexpression ( Figure 3A inset ) caused a 20% decrease in 17␤-estradiol transcriptional activity, as reflected by a decrease in relative fluorescence units normalized to the g of protein per well, compared with control cells treated with 17␤-estradiol but not H 2 O 2 (PϽ0.05; Figure 3A ). Second, we used HSP27-siRNA to reduce HSP27 protein levels in the same ERE reporter construct-transfected HeLa cells. Relative to oligofectamine or scrambled controls, siRNA dramatically reduced HSP27 protein expression ( Figure 3B ) and increased ERE output 44% and 59% compared with scrambled (nonsense) oligomers and oligofectamine, respectively ( Figure  3C ; ANOVA PϽ0.001, with PϽ0.05 for the mentioned comparisons). Taken together, these findings suggest that HSP27 is a corepressor of estrogen signaling mediated by ER␤.
Discussion
Nuclear receptor-associated proteins are important determinants of the cellular response to ligand-dependent and ligand-independent steroid hormone signaling. 1,9 Because we are interested in the vascular effects of estrogens, we sought to identify possible coregulatory proteins of ER␤, the ER isoform that shows transient mRNA overexpression after vascular injury. 11, 12 Using a yeast 2-hybrid screen, we discovered the association of HSP27, a recently recognized biomarker of atherosclerosis, with ER␤. 10 By way of various in vitro protein assays, we confirmed the interaction of HSP27 with ER␤ but not ER␣. Whereas MartinVentura et al recently noted decreased secretion of HSP27 in the supernatant of atherosclerotic carotid plaques compared with normal human arteries, these investigators did observe HSP27 immunopositive smooth muscle cells in atherosclerotic carotid endarterectomy specimens and normal mammary arteries. In contrast, we found an absence of HSP27 expression in coronary arteries with complex atherosclerotic lesions. There are several potential explanations for this discrepancy in the HSP27 immunolabeling results: (1) different arteries were examined (carotid versus coronary); (2i) perhaps the complexity of the atherosclerotic lesions differed; and (3) we used a monoclonal anti-HSP27 antibody whereas Martin-Ventura et al used a polyclonal anti-serum to HSP27. Although immunolabeling has its limitations, we were intrigued to find either an absence or presence of both HSP27 and ER␤ in all but 1 coronary artery from this population of young subjects. Whether the expression of these 2 proteins is linked requires further study. Interestingly, sex did not predict expression of ER␤ or HSP27. Heat shock proteins are highly conserved molecular chaperones that show upregulated expression in response to a range of cellular insults (eg, heat, oxidative stress, infection, cytokines) and play an active role in the stabilization and refolding of key intracellular proteins. 14 Although vascular smooth muscle and endothelial cells are known to express HSP27, the role of this protein in the vessel wall is only now beginning to be studied. Moreover, a number of studies report provocative associations between circulating heat shock protein levels or anti-heat shock protein antibodies and vascular disease. 15 Even though it has been known for more than a decade that HSP27 is induced by estrogens and in some way associated with estrogen receptors in various cells (eg, breast and endometrial tumors, platelets), these studies were completed before the discovery of ER␤. 16, 17 Our study is the first to report that HSP27 specifically associates with ER␤ and acts as a corepressor of estrogen signaling. Coregulatory proteins confer milieu-specific responses to steroid hormone receptors and altered levels of these factors play important roles in some diseases. For example, Gregory et al demonstrated that steroid receptor coactivators of the p160 family are expressed in the normal endometrium during the menstrual cycle but overexpressed in women with polycystic ovarian syndrome, and lead to poor reproductive function, endometrial hyperplasia, and cancer. 18 Similarly, as a corepressor of estrogen signaling, HSP27 may play a role in atherogenesis. However, the critical question that needs to be resolved is whether HSP27 loss contributes directly to coronary atherogenesis or if it is merely a secondary phenomenon that follows the accumulation of an atherosclerotic plaque? Given that induction of HSP27 with herbimycin A reduces neointimal hyperplasia in rat carotid arteries subjected to balloon injury, it is attractive to postulate that the relative absence of HSP27 may in fact be an important mechanistic step in atherogenesis. 19 For example, because many important vascular growth factors and cytokines have an ERE, it is conceivable that unregulated estrogen mediated transcription of these factors might occur in the absence of HSP27 and foster atherogenesis. 20 Hence, knowledge of an individual's HSP27 "status," perhaps reflected by a simple blood test, may be predictive of atherogenesis and who should receive estrogen therapy, because the development of undesirable side effects (eg, venous thrombosis, malignancy) could be caused by loss of HSP27 regulation of estrogen-mediated transcription. With studies of HSP27 ongoing in various patient populations, the usefulness of this biomarker in clinical management will soon be clarified.
